We are at the beginning of a new era of immunochemistry, namely the production of "antibody based" molecules.
Although the way ahead [for immunology] is full of pitfalls and difficulties, this is indeed an exhilarating prospect. There is no danger of a shortage of forthcoming excitement in the subject. Yet, as always, the highlights of tomorrow are the unpredictabilities of today.
What attracted me to immunology was that the whole thing seemed to revolve around a very simple experiment: take two different antibody molecules and compare their primary sequences. The secret of antibody diversity would emerge from that. Fortunately at the time I was sufficiently ignorant of the subject not to realise how naive I was being.
The hybridoma technology was a by-product of basic research. Its success in practical applications is to a large extent the result of unexpected and unpredictable properties of the method. It thus represents another clear-cut example of the enormous practical impact of an investment in research which might not have been considered commercially worthwhile, or of immediate medical relevance. It resulted from esoteric speculations, for curiosity's sake, only motivated by a desire to understand nature.
I learned what research was all about as a research student [with] Stoppani ... Max Perutz, and ... Fred Sanger... From them, I always received an unspoken message which in my imagination I translated as "Do good experiments, and don't worry about the rest."
And yet in a funny way our lack of success led to our breakthrough; because, since we could not get a cell line off the shelf doing what we wanted, we were forced to construct it. And the original experiment ... developed into a method for the production of hybridomas ... [which] was of more importance than our original purpose.
